182 related articles for article (PubMed ID: 9758341)
21. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
[TBL] [Abstract][Full Text] [Related]
22. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
Ergene U; Cağirgan S; Pehlivan M; Yilmaz M; Tombuloğlu M
Transfus Apher Sci; 2007 Feb; 36(1):23-9. PubMed ID: 17292672
[TBL] [Abstract][Full Text] [Related]
23. Mobilization and transplantation of peripheral blood stem cells.
Shadduck RK; Zeigler ZR; Andrews DF; Gilmore GL; Lister J
Stem Cells; 1998; 16 Suppl 1():145-58. PubMed ID: 11012157
[TBL] [Abstract][Full Text] [Related]
24. Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC).
Benet I; Prosper BF; Marugan I; Lluch A; Arbona C; Castillo I; Solano C; Garcia-Conde J
Bone Marrow Transplant; 1999 Jun; 23(11):1101-7. PubMed ID: 10382948
[TBL] [Abstract][Full Text] [Related]
25. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.
Bolwell B; Vredenburgh J; Overmoyer B; Gilbert C; Chap L; Menchaca DM; Cruickshank S; Glaspy J
Bone Marrow Transplant; 2000 Jul; 26(2):141-5. PubMed ID: 10918423
[TBL] [Abstract][Full Text] [Related]
26. Optimization of CD34+ collection for autologous transplantation using the evolution of peripheral blood cell counts after mobilization with chemotherapy and G-CSF.
Delamain MT; Metze K; Marques JF; Reis AR; De Souza CA; Lorand-Metze I
Transfus Apher Sci; 2006 Feb; 34(1):33-40. PubMed ID: 16376618
[TBL] [Abstract][Full Text] [Related]
27. Combined bone marrow and peripheral blood progenitor cell autografts for patients with poor mobilization.
Sinitsyn Y; Malone A; Mandeli J; Grosskreutz C; Osman K; Scigliano E; Shi P; Isola L
Cytotherapy; 2009; 11(4):457-63. PubMed ID: 19499401
[TBL] [Abstract][Full Text] [Related]
28. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
[TBL] [Abstract][Full Text] [Related]
29. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
30. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.
Hicks ML; Lonial S; Langston A; Flowers C; Roback JD; Smith KJ; Mossavi Sai S; Teagarden D; Hamilton ES; Waller EK; Kaufman J
Transfusion; 2007 Apr; 47(4):629-35. PubMed ID: 17381621
[TBL] [Abstract][Full Text] [Related]
31. Hematopoietic engraftment of dimethyl sulfoxide-depleted autologous peripheral blood progenitor cells.
Akkök CA; Holte MR; Tangen JM; Ostenstad B; Bruserud O
Transfusion; 2009 Feb; 49(2):354-61. PubMed ID: 18980622
[TBL] [Abstract][Full Text] [Related]
32. Cell adhesion molecule expression on CD34+ cells in grafts and time to myeloid and platelet recovery after autologous stem cell transplantation.
Watanabe T; Dave B; Heimann DG; Jackson JD; Kessinger A; Talmadge JE
Exp Hematol; 1998 Jan; 26(1):10-8. PubMed ID: 9430509
[TBL] [Abstract][Full Text] [Related]
33. The importance of CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue.
Millar BC; Millar JL; Shepherd V; Blackwell P; Porter H; Cunningham D; Judson I; Treleaven J; Powles RL; Catovsky D
Bone Marrow Transplant; 1998 Sep; 22(5):469-75. PubMed ID: 9733270
[TBL] [Abstract][Full Text] [Related]
34. [Collection of hematopoietic progenitor cells from healthy donors].
Bojanić I; Cepulić BG; Mazić S
Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
[TBL] [Abstract][Full Text] [Related]
35. Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies.
Carral A; de la Rubia J; Martín G; Martínez J; Sanz G; Jarque I; Sempere A; Soler MA; Marty ML; Sanz MA
Bone Marrow Transplant; 2002 May; 29(10):825-32. PubMed ID: 12058232
[TBL] [Abstract][Full Text] [Related]
36. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
[TBL] [Abstract][Full Text] [Related]
37. LDH elevation after autologous stem cell transplantation.
Bolwell B; Pohlman B; Kalaycio M; Wise K; Goormastic M; Andresen S
Bone Marrow Transplant; 1999 Jul; 24(1):53-5. PubMed ID: 10435735
[TBL] [Abstract][Full Text] [Related]
38. [CD34+ cell dose and hematologic recovery in allogeneic peripheral blood stem cell transplantation].
Sawada H; Wake A; Yamasaki Y; Izumi Y
Rinsho Ketsueki; 2000 Jun; 41(6):500-6. PubMed ID: 10921350
[TBL] [Abstract][Full Text] [Related]
39. Quantitation of primitive and lineage-committed progenitors in mobilized peripheral blood for prediction of platelet recovery post autologous transplant.
Hogge DE; Lambie K; Sutherland HJ; Benny WB; Dalal B; Currie C; Barnett MJ; Eaves AC; Eaves CJ
Bone Marrow Transplant; 2000 Mar; 25(6):589-98. PubMed ID: 10734292
[TBL] [Abstract][Full Text] [Related]
40. The CD34+90+ cell dose does not predict early engraftment of autologous blood stem cells as well as the total CD34+ cell dose.
Stewart DA; Guo D; Luider J; Auer I; Klassen J; Morris D; Chaudhry A; Brown C; Russell JA; Gluck S
Bone Marrow Transplant; 2000 Feb; 25(4):435-40. PubMed ID: 10723588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]